ArticleCommunications biology2025
FSCN1 regulates TGF-β signalling to promote esophageal squamous cell carcinoma metastasis via stabilizing THBS1 mRNA.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway.Clinical rheumatology · 2026Article
- FSCN1 drives sarcoma progression and immunosuppression revealed by pan-cancer analysis and functional assays.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC), the predominant histological subtype of esophageal cancer worldwide, is a leading cause of cancer-related mortality. Although Fascin actin-bundling protein 1 (FSCN1), an actin family member, is well-characterized for its role in facilitating tumor cell migration and invasion through cytoskeletal remodeling, its function as an RNA-binding protein remains poorly understood. Here we show that FSCN1 directly interacts with THBS1 mRNA via its RNA-binding capacity, with the binding localized to the coding sequence region. Functionally, FSCN1 stabilizes THBS1 transcripts to enhance protein expression, thereby activating TGF-β signaling to drive ESCC metastasis in vivo and in vitro, utilizing esophageal cancer cell lines and subcutaneous xenograft and lung metastasis models established in 8-week-old male BALB/c nu/nu nude mice. Clinically, FSCN1 and THBS1 are significantly co-overexpressed in ESCC tissues, correlating with advanced disease stages. Notably, hyperacetylation of FSCN1 attenuates its RNA-binding activity, leading to THBS1 mRNA destabilization and consequent suppression of metastatic potential. Our findings reveal a novel RNA-binding function of FSCN1 in posttranscriptional regulation of THBS1, establishing the FSCN1/THBS1/TGF-β axis as a critical driver of ESCC progression. The acetylation-dependent modulation of this pathway highlights the potential therapeutic vulnerability of metastatic ESCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.